Unilever, which has been below hearth from some traders for the group’s underperforming share worth, confirmed the method a few potential acquisition of the enterprise in a press release on Saturday.
“GSK Consumer Healthcare is a leader in the attractive consumer health space and would be a strong strategic fit as Unilever continues to re-shape its portfolio,” it mentioned.
“There can be no certainty that any agreement will be reached.”
GSK declined to touch upon the method.
Earlier, Britain’s Sunday Times mentioned the Unilever bid for the enterprise made late final 12 months was value roughly 50 billion kilos, and had been rejected as too low by GSK and Pfizer, which owns a minority stake in the division.
The method by Unilever, which owns manufacturers resembling Dove cleaning soap and Marmite, for Glaxo’s portfolio of family manufacturers together with Panadol painkillers and Sensodyne toothpaste was understood to have been unsolicited, it added.
Unilever’s bid didn’t embody any takeover premium or recognition of synergies, the newspaper mentioned, including that it was not clear whether or not the group would make the next supply.
Unilever has come below stress from traders after underperforming rivals resembling Procter & Gamble.
Chief Executive Alan (*50*) just lately bought right into a spat with British fund supervisor Terry Smith, who criticised the group for selling sustainability credentials on the expense of efficiency.
Brokerage Jefferies final 12 months put a valuation for the entire consumer unit at 45 billion kilos.
Deutsche Bank analysts mentioned in June 2021 that any takeover bid for GSK’s consumer property value greater than 45 billion kilos could be “eye-watering”.
Unilever has beforehand shot down solutions that it was in the marketplace for large offers. (*50*) has mentioned he was solely in small, bolt-on acquisitions in fast-growing areas resembling luxurious health and beauty and wellness.